SCHEMBL4510267

SCHEMBL4510267

[c]1occc1N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
HTT P42858 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CYP1A2 P05177 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALOX15 P16050 2/20 0.37
HSD17B10 Q99714 2/20 0.37
TP53 P04637 2/20 0.37
MAPK1 P28482 2/20 0.37
USP2 O75604 1/20 0.37
POLB P06746 1/20 0.37
PIK3CA P42336 2/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CB P42338 1/20 0.36
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3302046 0.83 CHKA (0.32) MAPTALDH1A1HTTMEN1KMT2A
SCHEMBL4677595 0.78 ADRB1 (0.41)
SCHEMBL4780502 0.67 HRH3 (0.47) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL9093746 0.66 LMNA (0.71) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL189494 0.65 LMNA (0.50) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL1607692 0.65 LMNA (0.41) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL8410646 0.65 LMNA (0.41) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL441105 0.63 LMNA (0.42) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL15475163 0.63 AR (0.39) LMNAMAPTALDH1A1HTTMEN1
SCHEMBL21177075 0.63 LMNA (0.42) LMNAMAPTALDH1A1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115151579-A Radical polymerization initiator, composition, cured product, and method for producing cured product 株式会社艾迪科 2022-10-04 CN disclosed
CN-115052861-A Compound, composition, cured product, and method for producing cured product 株式会社艾迪科 2022-09-13 CN disclosed
CN-114096568-A Composition, cured product, method for producing cured product, and additive 株式会社艾迪科 2022-02-25 CN disclosed
CN-113727967-A Compound, acid generator, composition, cured product, pattern, and method for producing cured product and pattern 株式会社艾迪科 2021-11-30 CN disclosed
CN-113727971-A Compound, acid generator, composition, cured product, pattern, and method for producing cured product and pattern 株式会社艾迪科 2021-11-30 CN disclosed
CN-104144912-B Compound and photosensitive polymer combination 株式会社艾迪科 2018-07-31 CN disclosed
CN-104144912-A NOVEL COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION ADEKA CORP 2014-11-12 CN disclosed
US-20090281099-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE ANDRES-GIL JOSE IGNACIO 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281099-A1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE ADRA2C, CHRNA5, ADRB2 LMNA 2952/4885MAPT 252/4885ALDH1A1 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.